The results seemed spectacularly good for patients on the higher doses.
In the subsequent phase III trial, two-thirds of participants received patisiran and one-third received a placebo. I was one of the 225 people enrolled in that study, which ran from November 2013 until August 2017. The results were published in July 2018 (D. Adams et al. N. Engl. J. Med. 379, 11-21; 2018) and found that the drug reduced TTR production by about 81%. The following month, patisiran was approved by both the US Food and Drug Administration and the European Medicines Agency (EMA). I was the patient representative at the EMA's meeting in London. It felt like a historic occasion. After 16 years of work and an investment of about US$3.5 billion by Alnylam into RNAi therapeutics, this was the start of a new era for people with hATTR. I was also a patient representative on the UK National Institute for Health and Care Excellence committee that decided in August to recommend that patisiran be used to treat damage to peripheral nerves due to hATTR amyloidosis.
Knowing that a drug exists that can stop the progression of a disease yet is not available to patients is extremely frustrating. Watching people get worse and die while a drug goes through the regulatory process is heartbreaking. But from a scientific point of view, it has been only 20 years since a new biological observation resulted in a drug being made widely available to patients. Twenty years is short from a scientific-development point of view. For a patient, it feels like a lifetime. Hereditary ATTR amyloidosis is an autosomal dominant condition, which means there is a 50% chance of each of my children having the gene for the disease. The proportion of people who carry the mutation and show symptoms is variable for unknown reasons. In Sweden, for example, it is around 20%, and in Portugal around 80%.
But from my perspective, the future looks bright for people with hATTR amyloidosis and their families. We now know that there is an effective treatment and that our children will not have to go through the pain and anxiety of this devastating disease.
A new form of the drug under development can be injected subcutaneously once every three months, instead of the current intravenous infusion every three weeks. This is thanks to advances in the chemistry of stabilizing the RNA. In the future, many diseases currently without treatment will be easily managed by a yearly injection of a specific siRNA.
Fifteen years after my initial diagnosis I remain reasonably well, with a good quality of life. I continue to work as a hand and wrist surgeon and thoroughly enjoy my job, carrying out operations and teaching the next generation of hand surgeons. I feel fortunate to be one of the first people to benefit from this new class of drug.
There are 7,000 recognized rare diseases, and hundreds of them should be treatable with RNAi therapeutics. Everything is out there to be done, and everything seems possible. ■
